Advertisement

Peptide Substrates of Dipeptidyl Peptidases

  • Inger Brandt
  • Anne-Marie Lambeir
  • Marie-Berthe Maes
  • Simon Scharpé
  • Ingrid De Meester
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

Keywords

Brain Natriuretic Peptide Vasoactive Intestinal Peptide Pituitary Adenylate Cyclase Activate Polypeptide Peptide Substrate Chemotactic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbott, CA, Yu, DM, Woollatt, E, Sutherland, GR, McCaughan GW, Gorrell MD, 2000, Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 267: 6140–6150.CrossRefPubMedGoogle Scholar
  2. Ahmad S, Wang L, Ward PE, 1992, Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther. 260: 1257–1261.PubMedGoogle Scholar
  3. Ahren B, 2003, Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 3: 365–372.PubMedGoogle Scholar
  4. Ahren B, Gomis R, Standl E, Mills D, Schweizer A, 2004, Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 27: 2874–2880.PubMedGoogle Scholar
  5. Ahren B, Hughes TE, 2005, Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like Peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing Peptide in mice. Endocrinology. 146: 2055–2059.CrossRefPubMedGoogle Scholar
  6. Ajami, K, Abbott, CA, McCaughan, GW, Gorrell MD, 2004, Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta. 1679: 18–28.PubMedGoogle Scholar
  7. Araki H, Li Y, Yamamoto Y, Haneda M, Nishi K, Kikkawa R, Ohkubo I, 2001, Purification, molecular cloning, and immunohistochemical localization of dipeptidyl peptidase II from the rat kidney and its identity with quiescent cell proline peptidase. J. Biochem. (Tokyo) 129: 279–288.PubMedGoogle Scholar
  8. Batterham RL, Bloom SR, 2003, The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 994: 162–168.PubMedCrossRefGoogle Scholar
  9. Bird AP, Faltinek JR, Shojaei AH, 2001, Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1. J Control Release. 73: 31–36.CrossRefPubMedGoogle Scholar
  10. Bonecchi R, Locati M, Galliera E, Vulcano M, Sironi M, Fra AM, Gobbi M, Vecchi A, Sozzani S, Haribabu B, Van Damme J, Mantovani A, 2004, Differential recognition and scavenging of native and truncated macrophagederived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol. 172: 4972–4976.PubMedGoogle Scholar
  11. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS, 2004, Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif. 37: 385–400.CrossRefPubMedGoogle Scholar
  12. Busek P, Malik R, Sedo A, 2004, Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 36: 408–421.CrossRefPubMedGoogle Scholar
  13. Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, Grouzmann E, 2005, Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 166: 433–442.PubMedGoogle Scholar
  14. Chen, YS, Chien, CH, Goparaju, CM, Hsu, JT, Liang, PH, Chen, X, 2004, Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells. Protein Expr Purif. 35: 142–146.CrossRefPubMedGoogle Scholar
  15. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM, 2005, Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther. 4: 351–360.CrossRefPubMedGoogle Scholar
  16. Chiravuri, M, Agarraberes, F, Mathieu, SL, Lee, H, Huber, BT, 2000, Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol. 165: 5695–5702.PubMedGoogle Scholar
  17. Christopherson KW 2nd, Hangoc G, Broxmeyer HE, 2002, Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 169: 7000–7008.PubMedGoogle Scholar
  18. Chronwall BM, Zukowska Z, 2004, Neuropeptide Y, ubiquitous and elusive. Peptides. 25: 359–363.CrossRefPubMedGoogle Scholar
  19. Cohen M, Fruitier-Arnaudin I, Piot JM, 2004, Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV. Biochimie. 86: 31–37.CrossRefPubMedGoogle Scholar
  20. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H, Tosato G, 2004, Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood. 103: 2452–2459CrossRefGoogle Scholar
  21. De Meester I, Lambeir AM, Proost P, Scharpe S, 2003, Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol. 524: 3–17.PubMedGoogle Scholar
  22. De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpe S, 2000, Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol. 477: 67–87.PubMedGoogle Scholar
  23. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL, 1997, Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 15: 673–677.CrossRefPubMedGoogle Scholar
  24. Drucker DJ, 2003, Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 26: 2929–2940.PubMedGoogle Scholar
  25. Eisenhauer, DA, McDonald, JK, 1986, A novel dipeptidyl peptidase II from the porcine ovary: purification and characterization of a lysosomal serine protease showing enhanced specificity for prolyl bonds. J Biol Chem. 261: 8859–8865.PubMedGoogle Scholar
  26. Forssmann U, Hartung I, Balder R, Fuchs B, Escher SE, Spodsberg N, Dulkys Y, Walden M, Heitland A, Braun A, Forssmann WG, Elsner J, 2004, n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. J Immunol. 173: 3456–3466.PubMedGoogle Scholar
  27. Fruitier-Arnaudin I, Cohen M, Coitoux C, Piot JM, 2003, In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase. Peptides. 24:1201–1206.CrossRefPubMedGoogle Scholar
  28. Fruitier-Arnaudin II, Cohen MM, Nervi SS, Bordenave SS, Sannier FF, Piot JM, 2003, Reduced level of opioid peptides, hemorphin-7 peptides, in serum of diabetic patients. Diabetes Care. 26: 2480.Google Scholar
  29. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS, 2005, Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol. In pressGoogle Scholar
  30. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J, 2003, Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 21: 566–569.CrossRefPubMedGoogle Scholar
  31. Gorrell MD, 2005, Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 108: 277–292.CrossRefGoogle Scholar
  32. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O’Harte FP, 2004, Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 428: 136–143.CrossRefPubMedGoogle Scholar
  33. Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O’Harte FP, Flatt PR, 2004, Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biol Chem. 385: 169–177.CrossRefPubMedGoogle Scholar
  34. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O’Harte FP, Flatt PR, 2004, N-terminal His(7)-modification of glucagon-like peptide-1(7–36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol. 180: 379–388.CrossRefPubMedGoogle Scholar
  35. Groneberg DA, Folkerts G, Peiser C, Chung KF, Fischer A, 2004, Neuropeptide Y (NPY). Pulm Pharmacol Ther. 17: 173–180.CrossRefPubMedGoogle Scholar
  36. Hall C, 2004, Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 6: 257–260.CrossRefPubMedGoogle Scholar
  37. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ, 2000, Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 141: 4013–4020.CrossRefPubMedGoogle Scholar
  38. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ, 2000, In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 85: 2884–2888.CrossRefPubMedGoogle Scholar
  39. Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kuhn-Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CH, 2000, Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagons degradation products and DPIV-resistant analogs. J Biol Chem. 275: 3827–3834.CrossRefPubMedGoogle Scholar
  40. Holst JJ, Deacon CF, 2004, Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 4: 589–596.CrossRefPubMedGoogle Scholar
  41. Islam MS, Rahman SA, Mirzaei Z, Islam KB, 2005, Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness. Life Sci. 76: 1239–1248.CrossRefPubMedGoogle Scholar
  42. Jiaang WT, Chen YS, Hsu T, Wu SH, Chien CH, Chang CN, Chang SP, Lee SJ, Chen X, 2005, Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 15: 687–691.CrossRefPubMedGoogle Scholar
  43. Karl T, Hoffmann T, Pabst R, von Horsten S, 2003, Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav. 75: 869–879.CrossRefPubMedGoogle Scholar
  44. Keire DA, Bowers CW, Solomon TE, Reeve JR Jr, 2002, Structure and receptor binding of PYY analogs. Peptides. 23: 305–321.CrossRefPubMedGoogle Scholar
  45. Khin EE, Kikkawa F, Ino K, Kajiyama H, Suzuki T, Shibata K, Tamakoshi K, Nagasaka T, Mizutani S, 2003, Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol. 188: 670–676.CrossRefPubMedGoogle Scholar
  46. Kieffer TJ, 2004, Gastro-intestinal hormones GIP and GLP-1. Ann Endocrinol (Paris). 65: 13–21.Google Scholar
  47. Kitlinska J, Lee EW, Li L, Pons J, Estes L, Zukowska Z, 2003, Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling. Adv Exp Med Biol. 524: 215–222.PubMedGoogle Scholar
  48. Kühn-Wache K, Hoffmann T, Manhart S, Brandt W, Demuth HU, 2003, The specificity of DP IV for natural substrates is peptide structure determined. Adv Exp Med Biol. 524: 57–63.PubMedGoogle Scholar
  49. Laing KJ, Secombes CJ, 2004, Chemokines. Dev Comp Immunol. 28: 443–460.CrossRefPubMedGoogle Scholar
  50. Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpé S, De Meester I, 2001, Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. 507: 327–330.CrossRefPubMedGoogle Scholar
  51. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpé S, Van Damme J, De Meester I, 2001, Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 276: 29839–29845.CrossRefPubMedGoogle Scholar
  52. Lambeir AM, Proost P, Scharpé S, De Meester I, 2002, A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol. 64: 1753–1756.CrossRefPubMedGoogle Scholar
  53. Lambeir AM, Durinx C, Scharpé S, De Meester I, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40: 209–294.PubMedGoogle Scholar
  54. Lankas G, Leiting B, Roy RS, Eiermann G, Biftu T, Kim D, Ok H, Weber A, Thornberry NA, 2004, Inhibition of DPP8/9 results in toxicity in preclinical species: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of Type 2 DM. Diabetes (suppl.2) 53, A2, 7-OR (Abstract).Google Scholar
  55. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA, 2004, A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood. 103: 3783–3788.CrossRefPubMedGoogle Scholar
  56. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC, 2005, Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem. 16: 377–382.CrossRefPubMedGoogle Scholar
  57. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT, Thornberry NA, 2003, Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV, VII. Biochem J. 371: 525–532.CrossRefPubMedGoogle Scholar
  58. Lin S, Boey D, Herzog H, 2004, NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides. 38: 189–200.CrossRefPubMedGoogle Scholar
  59. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E, 2002, Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol. 72: 183–191.PubMedGoogle Scholar
  60. Maes MB, Lambeir AM, Gilany K, Senten K, Van der Veken P, Leiting B, Augustyns K, Scharpe S, De Meester I, 2005, Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J. 386: 315–324.CrossRefPubMedGoogle Scholar
  61. McDonald, JK, Leibach, FH, Grindeland, RE, Ellis S, 1968, Purification of dipeptidyl aminopeptidase II (dipeptidyl arylamidase II) of the anterior pituitary gland: peptidase and dipeptide esterase activities. J Biol Chem. 243: 4143–4150.PubMedGoogle Scholar
  62. Mentlein, R, Struckhoff, G, 1989, Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 52: 1284–1293.CrossRefPubMedGoogle Scholar
  63. Mentlein R, 1999, Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulatory Peptides. 85: 9–24.CrossRefPubMedGoogle Scholar
  64. Mentlein R, Schiemann F, Ludwig A, Brandt E, 2003, Modification of the biological activity of chemokines by dipeptidyl peptidase IV-a side effect in the use of inhibitors? Adv Exp Med Biol. 524: 37–47.PubMedCrossRefGoogle Scholar
  65. Mizokami Y, Kajiyama H, Shibata K, Ino K, Kikkawa F, Mizutani S, 2004, Stromal cell-derived factor-1alphainduced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. Int J Cancer. 110: 652–659.CrossRefPubMedGoogle Scholar
  66. Munagala VK, Burnett JC Jr, Redfield MM, 2004, The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 29: 707–769.CrossRefPubMedGoogle Scholar
  67. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M, 2000, Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem. 275: 24003–24012.CrossRefPubMedGoogle Scholar
  68. Ohtsuki T, Hosono O, Kobayashi H, Munakata Y, Souta A, Shioda T, Morimoto C, 1998, Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidy peptidase IV. FEBS Lett. 431: 236–240.CrossRefPubMedGoogle Scholar
  69. Olsen C, Wagtmann N, 2002, Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene. 299: 185–193.CrossRefPubMedGoogle Scholar
  70. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA, 1997, Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 186: 1865–1872.CrossRefPubMedGoogle Scholar
  71. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ, 1999, Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 274: 36505–36512.CrossRefPubMedGoogle Scholar
  72. Pospisilik JA, Hinke SA, Pederson RA, Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CH, Demuth H, 2001, Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept. 96: 133–141.CrossRefPubMedGoogle Scholar
  73. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J, 1998, Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem. 273: 7222–7227.CrossRefPubMedGoogle Scholar
  74. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J, 1998, Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cellderived factor-1alpha. FEBS Lett. 432: 73–76.CrossRefPubMedGoogle Scholar
  75. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpe S, Van Damme J, De Meester I, 1999, Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 274: 3988–3993.CrossRefPubMedGoogle Scholar
  76. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J, 2000, Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood. 96: 1674–1680.PubMedGoogle Scholar
  77. Sadir R, Imberty A, Baleux F, Lortat-Jacob H, 2004, Heparan sulfate/heparin oligosaccharides protect stromal cellderived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem. 279: 43854–43860.CrossRefPubMedGoogle Scholar
  78. Sakurada C, Sakurada S, Hayashi T, Katsuyama S, Tan-No K, Sakurada T, 2003, Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol. 66: 653–661.CrossRefPubMedGoogle Scholar
  79. Schulz-Knappe P, Zucht HD, Heine G, Jurgens M, Hess R, Schrader M, 2001, Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb Chem High Throughput Screen. 4: 207–217.PubMedGoogle Scholar
  80. Senten K, Van Der Veken P, De Meester I, Lambeir AM, Scharpe S, Haemers A, Augustyns K, 2004, Gammaamino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J Med Chem. 47: 2906–2916.CrossRefPubMedGoogle Scholar
  81. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K, 2002, Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 316:129–135.CrossRefPubMedGoogle Scholar
  82. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y, 1998, Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A. 95: 6331–6336.CrossRefPubMedGoogle Scholar
  83. Silva AP, Cavadas C, Baisse-Agushi B, Spertini O, Brunner HR, Grouzmann E, 2003, NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. Regul Pept. 116: 71–79.CrossRefPubMedGoogle Scholar
  84. Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP, Detheux M, Parmentier M, De Meester I, Scharpe S, Van Damme J, 1999, CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 162: 4903–4909.PubMedGoogle Scholar
  85. Sun S, Albright CF, Fish BH, George HJ, Selling BH, Hollis GF, Wynn R, 2002, Expression, purification, and kinetic characterization of full-length human fibroblast activation protein. Protein Expr Purif. 24: 274–281.CrossRefPubMedGoogle Scholar
  86. Tavares W, Drucker DJ, Brubaker PL, 2000, Enzymatic-and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab. 278: E134–E139.PubMedGoogle Scholar
  87. Vanderheyden M, Bartunek J, Goethals M, 2004, Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 6: 261–268.CrossRefPubMedGoogle Scholar
  88. Weber AE, 2004, Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 47: 4135–4141.CrossRefPubMedGoogle Scholar
  89. Wrenger S, Kahne T, Bohuon C, Weglohner W, Ansorge S, Reinhold D, 2002, Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett. 466: 155–159.CrossRefGoogle Scholar
  90. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R, 2003, The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). J Biol Chem. 278: 22418–22423.CrossRefPubMedGoogle Scholar
  91. Li L, Demuth H-U, Zukowska Z, 2005, DPPIV: a molecular switch of vascular actions of neuropeptide Y. Chapter 14 of this book, 175–182.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Inger Brandt
    • 1
  • Anne-Marie Lambeir
    • 1
  • Marie-Berthe Maes
    • 1
  • Simon Scharpé
    • 1
  • Ingrid De Meester
    • 1
  1. 1.Laboratory of Medical Biochemistry, Department of Pharmaceutical SciencesUniversity of AntwerpAntwerpBelgium

Personalised recommendations